Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.

Abstract

BACKGROUND:

The first-generation integrase inhibitors (INIs) raltegravir (RAL) and elvitegravir (EVG) have shown efficacy against HIV infection, but they have the limitations of once-more daily dosing and extensive cross-resistance. Dolutegravir (DTG, S/GSK1349572), a second-generation drug that overcomes such shortcomings, is under spotlight. The purpose of this study is to review the evidence for DTG use in clinical settings, including its efficacy and safety.

METHODS:

PubMed, EMbase, Ovid, Web of Science, Science Direct, and related websites were screened from establishment until July 2013, and scientific meeting proceedings were manually searched. Two reviewers independently screened 118 citations repeatedly to identify randomized controlled trials comparing the efficacy and safety of DTG-based regimen with those of RAL- or elvitegravir-based regimens. Using the selected studies with comparable outcome measures and indications, we performed a meta-analysis based on modified intention-to-treat (mITT), on-treatment (OT), and as-treated (AT) virological outcome data. Independent data extraction and quality assessment were conducted.

RESULTS:

Four unique studies were included with the use of DTG in antiretroviral therapy-naive patients. In therapy-naive patients, DTG combined with abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC) resulted in a significantly better virological outcome with a mITT relative risk (RR)of 1.07 (95 % confidence interval (95 % CI 1.03-1.12). Evidence further supported use of DTG had a better virological suppression in the 50 mg once daily group (mITT RR 1.07; 95 % CI 1.03-1.12) as well as in the sub-analysis in dolutegravir/efavirenz(DTG/EFV) and dolutegravir/raltegravir (DTG/RAL) groups (RR 1.09, 95 % CI 1.03-1.15; RR 1.06, 95 % CI 0.98-1.15, respectively). In the matter of safety of DTG-based regimen, the risk of any event was RR 0.98 (95 % CI 0.94-1.01), the risk of serious adverse events (AEs) was RR 0.84 (95 % CI 0.62-1.15), and the risk of drug-related serious AEs was RR 0.33 (95 % CI 0.13-0.79).

CONCLUSION:

In general, DTG 50 mg given once daily combined with an active background drug is a better choice in terms of both efficacy and safety.

• Authors: Junjun Jiang, Xi Xu, Wenqin Guo, Jinming Su, Jiegang Huang, Bingyu Liang, Hui Chen, Ning Zang, Yanyan Liao, Li Ye, Hao Liang
• Journal: AIDS research and therapy (AIDS Res Ther) Vol. 13 Issue 1 Pg. 30 ( 2016) ISSN: 1742-6405 [Electronic] England
• PMID: 27617024 (Publication Type: Journal Article, Meta-Analysis, Review)

Chemical References

• Alkynes
• Anti-HIV Agents
• Benzoxazines
• Cyclopropanes
• Dideoxynucleosides
• Drug Combinations
• Heterocyclic Compounds, 3-Ring
• Oxazines
• Piperazines
• Pyridones
• abacavir, lamivudine drug combination
• Deoxycytidine
• Lamivudine
• Raltegravir Potassium
• Tenofovir
• dolutegravir
• efavirenz

Topics

• Alkynes
• Anti-HIV Agents (administration & dosage)
• Benzoxazines (administration & dosage)
• Cyclopropanes
• Deoxycytidine (administration & dosage)
• Dideoxynucleosides (administration & dosage)
• Drug Combinations
• HIV Infections (drug therapy, virology)
• HIV-1 (isolation & purification)
• Heterocyclic Compounds, 3-Ring (administration & dosage)
• Humans
• Lamivudine (administration & dosage)
• Oxazines
• Piperazines
• Pyridones
• Raltegravir Potassium (administration & dosage)
• Randomized Controlled Trials as Topic
• Tenofovir (administration & dosage)
• Treatment Outcome